The shareholders of Xbrane Biopharma AB, reg. no. 556749-2375, (the 'Company'), are hereby convened to the annual general meeting to be held on Thursday 16 May 2019, at 17.30 p.m. at Baker McKenzie's preemies at Vasagatan 7 in Stockholm.
The doors to the meeting will open at 17.00 p.m.
Right to attend the annual general meeting and notice: Shareholders wishing to attend the annual general meeting must: on the record date, which is Friday 10 May 2019, be registered in the share register maintained by Euroclear Sweden AB. Shareholders, whose shares are registered in the name of a nominee, must temporarily register the shares in their own name at Euroclear Sweden AB. Shareholders whose shares are registered in the name of a nominee must, no later than on Friday 10 May 2019, via their nominee, temporarily register the shares in their own name in order to be entitled to participate at the general meeting and notify their participation at the general meeting no later than Friday 10 May 2019. Notice of participation at the general meeting shall be sent by regular mail to Xbrane Biopharma AB, Banvaktsvagen 22, 171 48 Stockholm or by e-mail to firstname.lastname@example.org. Upon notification, the shareholder should state their full name, personal identification number or corporate registration number, address and telephone number, and, where applicable, details of representatives, proxy holders and advisors. A shareholder who wishes to be represented by proxy shall issue a written and dated proxy to the proxy holder. If the proxy is issued by a legal entity, a certified copy of the registration certificate or corresponding document ('Registration Certificate') shall be enclosed. The proxy must not be more than one year old, however, the proxy may be older if it is stated that it is valid for a longer term, maximum five years. The proxy in original and the Registration Certificate, if any, must be available at the general meeting and a copy should well before the meeting be sent to the Company by regular mail to Xbrane Biopharma AB, Banvaktsvagen 22, 171 48 Stockholm or by e-mail to email@example.com , and should, in order to facilitate the entrance to the general meeting, be at the Company's disposal no later than on 10 May 2019. A form proxy will be available for downloading on the Company's website www.xbrane.com.
Tel: +46 (0) 763-093 777
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser (firstname.lastname@example.org, +46 (0)8 409 421 20).
This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2019-04-16 14:15 CEST.
(C) 2019 Electronic News Publishing, source ENP Newswire